Evidence map›Paper›PMID 39384585›Full record

ArticlePediatric cardiology2025

Aspirin in Children; are There Not Two Sides of the Same Coin?

Dietmar Schranz

Abstract readLetter
In one paragraph

Article in Pediatric cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Percutaneous Deployment of the Sinus-SuperFlex-DS Stent for Hybrid Stage I Palliation in Neonates Weighing ≤ 2.5 kg: A Multicenter Study.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Dietmar SchranzDepartment of Pediatric Cardiology, Goethe University Clinic Frankfurt, Theodor-Stern-Kai 7, 60596, Frankfurt, Germany. dietmar.schranz@ukffm.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dose-dependent in vitro effects of aspirin on platelet inhibition and predictors of non-responsiveness have led to the recommendation of significantly higher doses of aspirin (5 mg/kg/day) in newborns and infants. The results are inconsistent with the pharmacodynamic effects of clopidogrel in newborns, where approximately 30% (0.2 mg/kg/day) of the adult dose (75 mg/day) showed equally effective antiaggregative effects. Consequently, the optimal aspirin dosage remains to be determined. The administration to newborns with congenital heart defects needs to address treatment goals, while accounting for the intricate interactions between platelets and endothelium, as well as the unique aspects of surgical and interventional procedures.

Indexed as

AspirinHeart Defects, CongenitalPlatelet Aggregation InhibitorsDose-Response Relationship, DrugHumansInfantInfant, NewbornAspirinPlatelet Aggregation InhibitorsAspirinCongenital heart diseaseDosageNeonates

Identifiers

PMID39384585
PMCPMC11746964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.